Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.04 -2.64 (-13.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation ↗

May 30, 2025

Summit now intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial.

Via Stocktwits

Topics Lawsuit Regulatory Compliance

Traders are paying attention to the gapping stocks in Friday's session. ↗

May 30, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure ↗

May 30, 2025

There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.

Via Investor's Business Daily

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint ↗

May 30, 2025

Summit Therapeutics' Phase 3 trial met the primary goal in lung cancer, showing significant PFS benefit with ivonescimab plus chemotherapy.

Via Benzinga

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025

From Summit Therapeutics Inc.

Via Business Wire

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

3 High-Flying Stocks That Could Soar Even More ↗

May 24, 2025

Via The Motley Fool

Treasury Yields Top 5%: These 20 Stocks Tanked In Just One Hour ↗

May 21, 2025

The selloff came as investors repriced risk across equities amid fears of persistently higher rates, sparked by soft demand at the 20-year Treasury auction.

Via Benzinga

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

May 21, 2025

Via The Motley Fool

Topics Economy Law Enforcement

Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money ↗

May 18, 2025

Via The Motley Fool

Topics Artificial Intelligence

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025

From Summit Therapeutics Inc.

Via Business Wire

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗

May 11, 2025

The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?

Via Benzinga

Can Summit Therapeutics Stock Double Your Money? ↗

May 07, 2025

Via The Motley Fool

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗

May 04, 2025

Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.

Via Benzinga

This Soaring Stock Just Delivered More Good News. Time to Buy? ↗

May 02, 2025

Via The Motley Fool

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 01, 2025

From Summit Therapeutics Inc.

Via Business Wire

9 Health Care Stocks Whale Activity In Today's Session ↗

April 28, 2025

Via Benzinga

Why Is Summit Therapeutics Stock Trading Higher On Monday? ↗

April 28, 2025

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial.

Via Benzinga

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗

April 28, 2025

Via Benzinga

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back ↗

April 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today ↗

April 25, 2025

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

April 25, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Via Chartmill

What's Going On With Summit Therapeutics Stock On Friday? ↗

April 25, 2025

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials.

Via Benzinga

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

April 25, 2025

From Summit Therapeutics Inc.

Via Business Wire

Top stock movements in today's session. ↗

April 25, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic ↗

April 25, 2025

The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.

Via Stocktwits

Topics Artificial Intelligence

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 25, 2025

Via Benzinga

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

April 24, 2025

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial ↗

April 23, 2025

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Via Stocktwits

Why Summit Therapeutics Rocketed Double-Digits Today ↗

April 23, 2025

Via The Motley Fool

Topics World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.